- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05352633
Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to evaluate the effect of intensive treatment (a target clinic based systolic BP <120mmHg) on 24-hour ambulatory blood pressure and home blood pressure, as well as the effect on White-coat uncontrolled hypertension and masked uncontrolled hypertension, compared with standard treatment (a target clinic based systolic BP <140mmHg). The population of this study is from an ongoing multi-centre open label clinical trial which evaluated the effect of intensive systolic hypertension treatment on major cardiac events (ESPRIT study). ESPRIT study enrolled patients with high risk of cardiovascular disease, who were aged≥50 years old with a systolic BP≥130 mmHg, and assigned them randomly to intense hypertension group (a target clinic based systolic BP <120mmHg) or standard hypertension group (a target clinic based systolic BP <140mmHg), with a 3-year follow-up, evaluating the effect of intense hypertension treatment on major cardiac events.
From those eligible ones for the trial, the investigators plan to select 710 to participate in this study. During the 2-3 years of follow-up of the main trial, the participants will be monitored using 24-hour ambulatory blood pressure monitoring, meanwhile one-week home blood pressure monitoring will also be conducted. The two monitoring approaches will be performed twice; once every half year, based on which this study will evaluate the effect of intensive hypertension treatment on 24-hour ambulatory blood pressure and home blood pressure, as well as the effect on White-coat uncontrolled hypertension and masked uncontrolled hypertension.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jing Li, Ph.D
- Email: jing.li@fwoxford.org
Study Contact Backup
- Name: Xiaofang Yan, M.S.
- Email: xiaofang.yan@fwoxford.org
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100037
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Ying Sun, B.A.
- Email: ying.sun@fwoxford.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- eligible for the follow up of the main study;
- content to participate in the sub-study.
Exclusion Criteria:
- frequently working during night-time;
- the non - dominant arm could not wear 24-hour ambulatory blood pressure monitoring due to radiation therapy or physical impairment;
- keep engaged in out-door activities of high physical intensity, e.g. farming or porter, etc.;
- life expectancy is less than 1 year; such as diagnosed with heart failure, cancer, or end-stage renal disease;
- the difference of clinical systolic pressure between upper arms was more than 10 mmHg;
- unable to use smart-phone to upload family blood pressure monitoring data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensive BP Arm
Participants randomized into the Intensive treatment group will have a goal of SBP <120 mmHg.
A two- or three-drug regimen should be initiated at randomization for most participants.
Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of <120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
|
Participants in the Intensive BP treatment group have a goal of SBP <120 mmHg.
It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed.
The local investigator may select among the available study antihypertensive medications.
Other drugs not supplied by the trial may also be used as the investigator determines appropriate.
One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
Other Names:
|
Active Comparator: Standard BP Arm
Participants randomized into the Standard treatment group will have a goal of SBP <140 mmHg.
It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible.
Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits.
Down titration should be carried out if the SBP is <130 mmHg at a single visit or <135 mmHg at two consecutive visits.
|
Participants in the Standard BP treatment group have a goal of SBP <140 mmHg.
The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences of the mean blood pressure during daytime
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to compare the differences of the mean blood pressure during daytime among different intervention groups
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with White-coat uncontrolled hypertension
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to examine the proportion of participants with White-coat uncontrolled hypertension
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Differences of the proportions of participants with White-coat uncontrolled hypertension among different intervention groups
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to compare the differences of the proportions of participants with White-coat uncontrolled hypertension among different intervention groups
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Proportion of participants with Masked uncontrolled hypertension
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to examine the proportion of participants with Masked uncontrolled hypertension
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Differences of the proportions of participants with Masked uncontrolled hypertension among different intervention groups
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to compare the differences of the proportions of participants with Masked uncontrolled hypertension among different intervention groups
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Differences of mean blood pressure during night-time
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to compare the differences of mean blood pressure during night-time among different intervention groups.
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Differences of 24-hour mean blood pressure
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to compare the differences of 24-hour mean blood pressure among different intervention groups.
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Differences of the ratios of night-time and daytime blood pressure
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to compare the differences of the ratios of night-time and daytime blood pressure among different intervention groups.
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Differences of mean systolic blood pressure via home blood pressure monitoring
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, to compare the differences of mean systolic blood pressure via home blood pressure monitoring among different intervention groups.
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Compare the consistency of clinic-based blood pressure and out-office blood pressure
Time Frame: During the 2-3 years of follow-up of the main trial (ESPRIT)
|
During the 2-3 years of follow-up of the main trial, among participants from different intervention groups (intensive and standard groups), to compare the consistency of clinic-based blood pressure and out-office blood pressure (mean SBP during daytime vs mean home blood pressure )
|
During the 2-3 years of follow-up of the main trial (ESPRIT)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jing Li, Chinese Academy of Medical Sciences, Fuwai Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SFLX2021014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Pressure
-
SE HealthCentre for Aging and Brain Health InnovationCompletedHypertension | Blood Pressure | Hypotension | High Blood Pressure | Low Blood PressureCanada
-
DongGuk UniversityActive, not recruitingHypertension | Blood Pressure | Ambulatory Blood Pressure | Home Blood Pressure MeasurementKorea, Republic of
-
ROX Medical, Inc.CompletedHypertension | Blood Pressure, High | Blood Pressure, Resistant | Blood Pressure, UncontrolledUnited Kingdom, Netherlands, Belgium
-
University of JordanCompletedBlood Pressure | Heart Rate | Airway PressureJordan
-
Istituto Auxologico ItalianoRecruitingArterial Hypertension | Ambulatory Blood Pressure Monitoring | Blood Pressure Determination | Home Blood Pressure MonitoringItaly
-
RadiRad Co., Ltd.Hualien Tzu Chi General HospitalNot yet recruitingBlood Pressure
-
Riphah International UniversityRecruiting
-
GE HealthcareNot yet recruiting
-
Guangdong Provincial People's HospitalRecruiting
-
Guangdong Provincial People's HospitalRecruiting
Clinical Trials on Intensive BP Arm
-
University of MinnesotaMayo Clinic; University of Pennsylvania; University of Alabama at Birmingham; Vanderbilt... and other collaboratorsCompleted
-
Shanghai Institute of HypertensionRecruiting
-
Cedars-Sinai Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); University of Texas Southwestern... and other collaboratorsCompleted
-
Case Western Reserve UniversityCompleted
-
Samsung Medical CenterNot yet recruiting
-
University of NebraskaRecruitingHemiplegic Cerebral PalsyUnited States
-
Inje UniversityUnknownBOWEL PREPARATION (BOWEL CLEANSING)Korea, Republic of
-
The George Institute for Global Health, ChinaChanghai HospitalTerminatedAcute Ischemic StrokeChina
-
Nanjing First Hospital, Nanjing Medical UniversityTerminated
-
Karolinska InstitutetNorrbacka-Eugenia Foundation; Swedish Rheumatism Foundation; Svenska Diabetes...CompletedPsychosocial Treatment Intervention in Persons Newly Diagnosed With Rheumatoid Arthritis or DiabetesDiabetes Mellitus | Arthritis, Rheumatoid | Coping SkillsSweden